KaloBios Pharmaceuticals, Inc. Completes $4 Million In Seed Funding From Sofinnova Ventures And Alloy Ventures

KaloBios, a therapeutic antibody company and developer of proprietary platforms for the discovery of therapeutic proteins and antibodies, announced today the closing of a seed investment round of $4 million. Sofinnova Ventures and Alloy Ventures participated in the financing. Jim Healy, M.D., Ph.D., Managing Director of Sofinnova Ventures, and Doug Kelly, M.D., General Partner of Alloy Ventures, serve on KaloBios’ board.